J&J backs out of RSV vaccine race with rivals Pfizer and GSK
Publishing timestamp: 2023-03-29 14:39:57
Summary
J&J has announced that it is discontinuing its investigational RSV adult vaccine program and stopping the pivotal phase three trial testing the shot. The decision comes after Pfizer and GSK made major strides towards U.S. approval of their RSV shots last month. RSV is a common virus that can cause serious infections in older adults and infants, leading to hospitalization or death. J&J's decision was attributed to a portfolio review to prioritize the most transformational assets for ongoing investment.
Sentiment: NEUTRAL
Tickers: GSK-GB, JNJ, MRNA, PFE, GSK,
Keywords: gsk plc, biotechnology, business news, business, pharmaceuticals, health care industry, moderna inc, johnson & johnson, pfizer inc, biotech and pharmaceuticals, breaking news, breaking news: business,
Source: https://www.cnbc.com/2023/03/29/jj-backs-out-of-rsv-vaccine-race-with-rivals-pfizer-and-gsk-.html